Literature DB >> 14642305

Porin of Shigella dysenteriae enhances mRNA levels for Toll-like receptor 2 and MyD88, up-regulates CD80 of murine macrophage, and induces the release of interleukin-12.

Avijit Ray1, Nabendu S Chatterjee, Sujit K Bhattacharya, Tapas Biswas.   

Abstract

Sera of patients convalescing from shigellosis reacted strongly and specifically with the 38,000 Da monomer of porin of Shigella dysenteriae type 1. Since human, the only natural host of S. dysenteriae type 1, recognized the protein through humoral immune response, it is of great significance to study the surface-exposed outer membrane antigen as an adjuvant. Porin treatment of CD11b+ peritoneal cavity (PerC) MPhi of BALB/c mouse was found to up-regulate CD80 on cell surface and had no effect on CD86 expression. The surface expression of CD80 got increased by 1.6-fold in the presence of gamma interferon (IFN-gamma) supporting selective regulation of the B7-1 (CD80) member of the B7 family. MPhi released 7.25 pg of interleukin-12 (IL-12) in the presence of porin. The protein in combination with IFN-gamma augmented profoundly the release of IL-12 by 2.6-fold. Porin-mediated induction of IL-12 release would therefore influence Th1-type response, known to be preferentially triggered due to up-regulation of CD80 expression. Treatment of PerC MPhi by the protein showed an increase of mRNA for both Toll-like receptor (TLR)2 and myeloid differentiation factor 88 (MyD88) by 2- and 2.3-fold respectively, emphasizing that TLR2 is essential for recognition of S. dysenteriae type 1 porin. Understanding the mechanism of adjuvanticity of porin of S. dysenteriae type 1 is a necessary step towards the development of a better adjuvant against shigellosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642305     DOI: 10.1016/S0928-8244(03)00233-5

Source DB:  PubMed          Journal:  FEMS Immunol Med Microbiol        ISSN: 0928-8244


  8 in total

Review 1.  Innate immune function of the neisserial porins and the relationship to vaccine adjuvant activity.

Authors:  Lee M Wetzler
Journal:  Future Microbiol       Date:  2010-05       Impact factor: 3.165

2.  Structural basis for solute transport, nucleotide regulation, and immunological recognition of Neisseria meningitidis PorB.

Authors:  Mikio Tanabe; Crina M Nimigean; T M Iverson
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-29       Impact factor: 11.205

3.  Porin of Shigella dysenteriae enhances Toll-like receptors 2 and 6 of mouse peritoneal B-2 cells and induces the expression of immunoglobulin M, immunoglobulin G2a and immunoglobulin A.

Authors:  Avijit Ray; Tapas Biswas
Journal:  Immunology       Date:  2005-01       Impact factor: 7.397

4.  Role of constitutive androstane receptor in Toll-like receptor-mediated regulation of gene expression of hepatic drug-metabolizing enzymes and transporters.

Authors:  Pranav Shah; Tao Guo; David D Moore; Romi Ghose
Journal:  Drug Metab Dispos       Date:  2013-11-05       Impact factor: 3.922

5.  Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages.

Authors:  Leah E Cole; Kari Ann Shirey; Eileen Barry; Araceli Santiago; Prasad Rallabhandi; Karen L Elkins; Adam C Puche; Suzanne M Michalek; Stefanie N Vogel
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

6.  The PorB porin from commensal Neisseria lactamica induces Th1 and Th2 immune responses to ovalbumin in mice and is a potential immune adjuvant.

Authors:  Xiuping Liu; Lee M Wetzler; Paola Massari
Journal:  Vaccine       Date:  2007-12-26       Impact factor: 3.641

Review 7.  Microbe-host interactions: structure and role of Gram-negative bacterial porins.

Authors:  Stefania Galdiero; Annarita Falanga; Marco Cantisani; Rossella Tarallo; Maria Elena Della Pepa; Virginia D'Oriano; Massimiliano Galdiero
Journal:  Curr Protein Pept Sci       Date:  2012-12       Impact factor: 3.272

Review 8.  Immune Adjuvant Effect of Molecularly-defined Toll-Like Receptor Ligands.

Authors:  Deana N Toussi; Paola Massari
Journal:  Vaccines (Basel)       Date:  2014-04-25
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.